Covaxin for Children: Study says robust safety, immunogenicity in 2-18 year old volunteers

Covaxin for Children: Study says robust safety, immunogenicity in 2-18 year old volunteers

Bharat Biotech had conducted phase II/III, open-label, and multicenter studies to evaluate the safety, reactogenicity, and immunogenicity of Covaxin in healthy children and adolescents in the 2-18 age group, a press release from the vaccine maker said. Bharat Biotech International Limited (BBIL), on Thursday announced that BBV152 (Covaxin), its whole-virion inactivated COVID-19 vaccine candidate, has … Read more

DGCI nod to Covaxin for use in children above 12 years with certain conditions

DGCI nod to Covaxin for use in children above 12 years with certain conditions

The Subject Expert Committee on COVID-19 of the CDSCO on October 12 after deliberating Bharat Biotech’s EUA application had recommended granting emergency use approval to Covaxin for use in the 12-18 years age group with certain conditions. The Drugs Controller General of India (DCGI) has granted emergency use authorisation to indigenously-developed Bharat Biotech’s Covaxin for … Read more

Experts hail Covaxin approval for 2-18 year olds, favour use on children with comorbidities first

Experts hail Covaxin approval for 2-18 year olds, favour use on children with comorbidities first

The just approved vaccine from Bharat Biotech is for 2 to 18 year olds. Children in India now have a choice in terms of COVID-19 vaccines with Bharat Biotech becoming the second company after Zydus Cadila to offer a vaccine for children. Off course, the Zydus Cadila vaccine, is a first in the world DNA … Read more